Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Neurovascular Research
  4. Volume 21, Issue 3
  5. Article
Volume 21, Issue 3
  • ISSN: 1567-2026
  • E-ISSN: 1875-5739

Abstract

Background

Interleukin-6 (IL-6) plays an important role   in   the   pathophysiology   of atherosclerosis. This study aimed to determine whether IL-6 is a crucial biomarker associated with Multiple Acute Infarctions (MAIs), which indicate   an   important   stroke   mechanism of artery-to-artery embolism with a high risk of stroke recurrence in symptomatic Intracranial Atherosclerotic Disease (sICAD). We tested the association between circulating IL-6 levels and the presence of MAIs in a prospective population-based registry.

Methods

We included 1,919 patients with sICAD and baseline IL-6 levels from the Third China National Stroke Registry for the current analysis, The baseline IL-6 was centrally measured at Beijing Tiantan Hospital, Images of the brain parenchyma and vascular structures were digitized and then blindly and independently read by two groups of trained readers, The recruited patients were divided into 3 groups according to IL-6 tertiles, The relationship between baseline IL-6 tertile levels and the presence of MAIs was modeled using multivariate logistic regression.

Results

Compared to patients in the first IL-6 tertile those in the second and third tertiles demonstrated a significantly higher proportion of MAIs. The odds ratios were 1.81 [95% Confidence Interval (CI), 1.42-2.30] for the second first tertile and 2.15 (95% CI 1.66-2.79) for the third first tertile, The proportion of patients with MAIs increased with rising IL-6 tertiles observed at 59.3%, 71.6% and 76.4% for the first, second and third tertiles, respectively ( for trend < 0.001). The association between higher IL-6 tertiles and increased proportion of MAIs was also present in subgroups defined by age < 65 years, age ≥ 65 years, male, and high-sensitivity C-reactive Protein (hs-CRP) ≥ 2 mg/L. Furthermore, a significant interaction was detected for the hs-CRP subgroup ( = 0.038). In sensitivity analyses, the positive correlation between IL-6 levels and the proportion of MAIs remained consistent.

Conclusion

In patients with sICAD, higher IL-6 levels were associated with an increased proportion of MAIs. IL-6 could be used as a biomarker and a potential therapeutic target for future atherosclerosis treatment and prevention in patients with sICAD.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnr/10.2174/0115672026323216240722194958
2024-07-25
2025-01-15

  • From This Site

    /content/journals/cnr/10.2174/0115672026323216240722194958
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. GutierrezJ. TuranT.N. HohB.L. ChimowitzM.I. Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment.Lancet Neurol.202221435536810.1016/S1474‑4422(21)00376‑835143758
     [Google Scholar]
  2. ChenZ. QinH. LiuJ. WuB. ChengZ. JiangY. LiuL. JingL. LengX. JingJ. WangY. WangY. Characteristics of wall shear stress and pressure of intracranial atherosclerosis analyzed by a computational fluid dynamics model: A pilot study.Front. Neurol.2020100137210.3389/fneur.2019.0137232010041
     [Google Scholar]
  3. PuigN. SoléA. Aguilera-SimonA. GriñánR. RotllanN. Camps-RenomP. BenitezS. Novel therapeutic approaches to prevent atherothrombotic ischemic stroke in patients with carotid atherosclerosis.Int. J. Mol. Sci.202324181432510.3390/ijms24181432537762627
     [Google Scholar]
  4. GaoS. WangY.J. XuA.D. LiY.S. WangD.Z. Chinese ischemic stroke subclassification.Front. Neurol.20112610.3389/fneur.2011.0000621427797
     [Google Scholar]
  5. KhanM. NaqviI. BansariA. KamalA.K. Intracranial atherosclerotic disease.Stroke Res. Treat.20112011028284521772967
     [Google Scholar]
  6. BentzonJ.F. OtsukaF. VirmaniR. FalkE. Mechanisms of plaque formation and rupture.Circ. Res.2014114121852186610.1161/CIRCRESAHA.114.30272124902970
     [Google Scholar]
  7. WilliamJ. Correction to: Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the american heart association/american stroke association.Stroke20195012e440e44131765293
     [Google Scholar]
  8. PrapiadouS. ŽivkovićL. ThorandB. GeorgeM.J. van der LaanS.W. MalikR. HerderC. KoenigW. UelandT. KlevelandO. AukrustP. GullestadL. BernhagenJ. PasterkampG. PetersA. HingoraniA.D. RosandJ. DichgansM. AndersonC.D. GeorgakisM.K. Proteogenomic data integration reveals CXCL10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosis.Circulation2024149966968310.1161/CIRCULATIONAHA.123.06497438152968
     [Google Scholar]
  9. HuberS.A. SakkinenP. ConzeD. HardinN. TracyR. Interleukin-6 exacerbates early atherosclerosis in mice.Arterioscler. Thromb. Vasc. Biol.199919102364236710.1161/01.ATV.19.10.236410521365
     [Google Scholar]
  10. BiscettiF. TinelliG. RandoM.M. NardellaE. CecchiniA.L. AngeliniF. StrafaceG. FilipponiM. ArenaV. PitoccoD. GasbarriniA. MassettiM. FlexA. Association between carotid plaque vulnerability and high mobility group box-1 serum levels in a diabetic population.Cardiovasc. Diabetol.202120111410.1186/s12933‑021‑01304‑834044825
     [Google Scholar]
  11. Kamtchum-TatueneJ. SabaL. HeldnerM.R. PoorthuisM.H.F. de BorstG.J. RundekT. KakkosS.K. ChaturvediS. TopakianR. PolakJ.F. JicklingG.C. Interleukin-6 predicts carotid plaque severity, vulnerability, and progression.Circ. Res.20221312e22e3310.1161/CIRCRESAHA.122.32087735713008
     [Google Scholar]
  12. BambroughP. PeverelliM. BrownA.J. GiblettJ.P. BennettM.R. WestN.E.J. HooleS.P. Trans-myocardial blood interleukin-6 levels relate to intracoronary imaging-defined features of plaque vulnerability and predict procedure-induced myocardial infarction.Cardiovasc. Revasc. Med.202239061110.1016/j.carrev.2021.10.00634670726
     [Google Scholar]
  13. WangY. JingJ. MengX. PanY. WangY. ZhaoX. LinJ. LiW. JiangY. LiZ. ZhangX. YangX. JiR. WangC. WangZ. HanX. WuS. JiaZ. ChenY. LiH. The Third China National Stroke Registry (CNSR-III) for patients with acute ischaemic stroke or transient ischaemic attack: design, rationale and baseline patient characteristics.Stroke Vasc. Neurol.20194315816410.1136/svn‑2019‑00024231709123
     [Google Scholar]
  14. ChimowitzM.I. LynnM.J. Howlett-SmithH. SternB.J. HertzbergV.S. FrankelM.R. LevineS.R. ChaturvediS. KasnerS.E. BeneschC.G. SilaC.A. JovinT.G. RomanoJ.G. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.N. Engl. J. Med.2005352131305131610.1056/NEJMoa04303315800226
     [Google Scholar]
  15. ChimowitzM.I. LynnM.J. DerdeynC.P. TuranT.N. FiorellaD. LaneB.F. JanisL.S. LutsepH.L. BarnwellS.L. WatersM.F. HohB.L. HourihaneJ.M. LevyE.I. AlexandrovA.V. HarriganM.R. ChiuD. KlucznikR.P. ClarkJ.M. McDougallC.G. JohnsonM.D. PrideG.L.Jr TorbeyM.T. ZaidatO.O. RumboldtZ. CloftH.J. Stenting versus aggressive medical therapy for intracranial arterial stenosis.N. Engl. J. Med.201136511993100310.1056/NEJMoa110533521899409
     [Google Scholar]
  16. JingJ. MengX. ZhaoX. LiuL. WangA. PanY. LiH. WangD. JohnstonS.C. WangY. WangY. Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns.JAMA Neurol.201875671171910.1001/jamaneurol.2018.024729582084
     [Google Scholar]
  17. McCabeJ.J. WalshC. GoreyS. HarrisK. HervellaP. Iglesias-ReyR. JernC. LiL. MiyamotoN. MontanerJ. PedersenA. PurroyF.F. RothwellP.M. SudlowC.L. UenoY. Vicente-PascualM. WhiteleyW.N. WoodwardM. KellyP.J. C-reactive protein, interleukin-6, and vascular recurrence according to stroke subtype.Neurology20241022e20801610.1212/WNL.000000000020801638165328
     [Google Scholar]
  18. ChaturvediS. De MarchisG.M. Inflammatory biomarkers and stroke subtype.Neurology20241022e20809810.1212/WNL.000000000020809838165352
     [Google Scholar]
  19. ZietzA. GoreyS. KellyP.J. KatanM. McCabeJ.J. Targeting inflammation to reduce recurrent stroke.Int. J. Stroke202419437938710.1177/1747493023120777737800305
     [Google Scholar]
  20. RidkerP.M. EverettB.M. ThurenT. MacFadyenJ.G. ChangW.H. BallantyneC. FonsecaF. NicolauJ. KoenigW. AnkerS.D. KasteleinJ.J.P. CornelJ.H. PaisP. PellaD. GenestJ. CifkovaR. LorenzattiA. ForsterT. KobalavaZ. Vida-SimitiL. FlatherM. ShimokawaH. OgawaH. DellborgM. RossiP.R.F. TroquayR.P.T. LibbyP. GlynnR.J. CANTOS Trial Group Antiinflammatory therapy with canakinumab for atherosclerotic disease.N. Engl. J. Med.2017377121119113110.1056/NEJMoa170791428845751
     [Google Scholar]
  21. KaptogeS. SeshasaiS.R.K. GaoP. FreitagD.F. ButterworthA.S. BorglykkeA. Di AngelantonioE. GudnasonV. RumleyA. LoweG.D.O. JørgensenT. DaneshJ. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis.Eur. Heart J.201435957858910.1093/eurheartj/eht36724026779
     [Google Scholar]
  22. PattersonC.C. SmithA.E. YarnellJ.W.G. RumleyA. Ben-ShlomoY. LoweG.D.O. The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: The Caerphilly Study.Atherosclerosis2010209255155710.1016/j.atherosclerosis.2009.09.03019836021
     [Google Scholar]
  23. SarwarN. ButterworthA.S. FreitagD.F. GregsonJ. WilleitP. GormanD.N. GaoP. SaleheenD. RendonA. NelsonC.P. BraundP.S. HallA.S. ChasmanD.I. Tybjærg-HansenA. ChambersJ.C. BenjaminE.J. FranksP.W. ClarkeR. WildeA.A. TripM.D. SteriM. WittemanJ.C. QiL. van der SchootC.E. de FaireU. ErdmannJ. StringhamH.M. KoenigW. RaderD.J. MelzerD. ReichD. PsatyB.M. KleberM.E. PanagiotakosD.B. WilleitJ. WennbergP. WoodwardM. AdamovicS. RimmE.B. MeadeT.W. GillumR.F. ShafferJ.A. HofmanA. OnatA. SundströmJ. Wassertheil-SmollerS. MellströmD. GallacherJ. CushmanM. TracyR.P. KauhanenJ. KarlssonM. SalonenJ.T. WilhelmsenL. AmouyelP. CantinB. BestL.G. Ben-ShlomoY. MansonJ.E. Davey-SmithG. de BakkerP.I. O’DonnellC.J. WilsonJ.F. WilsonA.G. AssimesT.L. JanssonJ.O. OhlssonC. TivestenÅ. LjunggrenÖ. ReillyM.P. HamstenA. IngelssonE. CambienF. HungJ. ThomasG.N. BoehnkeM. SchunkertH. AsselbergsF.W. KasteleinJ.J. GudnasonV. SalomaaV. HarrisT.B. KoonerJ.S. AllinK.H. NordestgaardB.G. HopewellJ.C. GoodallA.H. RidkerP.M. HólmH. WatkinsH. OuwehandW.H. SamaniN.J. KaptogeS. Di AngelantonioE. HarariO. DaneshJ. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.Lancet201237998221205121310.1016/S0140‑6736(11)61931‑422421339
     [Google Scholar]
  24. OkazakiS. SakaguchiM. MiwaK. FurukadoS. YamagamiH. YagitaY. MochizukiH. KitagawaK. Association of interleukin-6 with the progression of carotid atherosclerosis: a 9-year follow-up study.Stroke201445102924292910.1161/STROKEAHA.114.00599125139874
     [Google Scholar]
  25. KellyP.J. LemmensR. TsivgoulisG. Inflammation and stroke risk: A new target for prevention.Stroke20215282697270610.1161/STROKEAHA.121.03438834162215
     [Google Scholar]
  26. YudkinJ.S. KumariM. HumphriesS.E. Mohamed-AliV. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?Atherosclerosis2000148220921410.1016/S0021‑9150(99)00463‑310657556
     [Google Scholar]
  27. SchiefferB. SelleT. HilfikerA. Hilfiker-KleinerD. GroteK. TietgeU.J.F. TrautweinC. LuchtefeldM. SchmittkampC. HeenemanS. DaemenM.J.A.P. DrexlerH. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis.Circulation2004110223493350010.1161/01.CIR.0000148135.08582.9715557373
     [Google Scholar]
  28. GuoF. DongM. RenF. ZhangC. LiJ. TaoZ. YangJ. LiG. Association between local interleukin-6 levels and slow flow/microvascular dysfunction.J. Thromb. Thrombolysis201437447548210.1007/s11239‑013‑0974‑024242026
     [Google Scholar]
  29. FengY. YeD. WangZ. PanH. LuX. WangM. XuY. YuJ. ZhangJ. ZhaoM. XuS. PanW. YinZ. YeJ. WanJ. The role of interleukin-6 family members in cardiovascular diseases.Front. Cardiovasc. Med.20229081889010.3389/fcvm.2022.81889035402550
     [Google Scholar]
  30. McCabeJ.J. O’ReillyE. CoveneyS. CollinsR. HealyL. McManusJ. MulcahyR. MoynihanB. CassidyT. HsuF. WorrallB. MurphyS. O’DonnellM. KellyP.J. Interleukin-6, C-reactive protein, fibrinogen, and risk of recurrence after ischaemic stroke: Systematic review and meta-analysis.Eur. Stroke J.202161627110.1177/239698732098400333817336
     [Google Scholar]
/content/journals/cnr/10.2174/0115672026323216240722194958
Loading
Association between Interleukin-6 and Multiple Acute Infarctions in Symptomatic Intracranial Atherosclerotic Disease
Curr Neurovasc Res 21, 292 (2024); https://doi.org/10.2174/0115672026323216240722194958
/content/journals/cnr/10.2174/0115672026323216240722194958
/content/journals/cnr/10.2174/0115672026323216240722194958
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): atherosclerosis; inflammation; Interleukin-6; ischemic stroke; multiple acute infarctions; symptomatic intracranial atherosclerotic disease

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test